More News

06 Mar 2019 AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes
06 Mar 2019 Glenmark Pharmaceuticals Announces Appointment of Alessandro Riva as CEO of its New Innovation Company
06 Mar 2019 Iksuda Therapeutics and Femtogenix sign license agreement
05 Mar 2019 Numab Announces Entry into a License Agreement With Intarcia for Anti-Inflammatory ND016
05 Mar 2019 Xenetic Biosciences, Inc. Announces Agreement to Acquire Innovative CAR T Technology Platform
04 Mar 2019 Adagene Announces a Platform Evaluation of the Dynamic Precision Library with Celgene Corporation
04 Mar 2019 NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
04 Mar 2019 Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology
02 Mar 2019 AdoRx Therapeutics Announces Collaboration With Johnson & Johnson Innovation to Develop Novel Lung Cancer Therapeutics
02 Mar 2019 MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company
28 Feb 2019 Abpro and NJCTTQ Enter Into Partnership for Development of Multiple Novel Bispecific Antibodies
28 Feb 2019 Sarepta Exercises Option to Acquire Myonexus Therapeutics
27 Feb 2019 Imbrium Therapeutics and TetraGenetics Announce Strategic Research Collaboration and License Option to Develop Novel Biologic Therapeutics for Pain
27 Feb 2019 Selexis SA and Turgut Pharmaceuticals Expand Biosimilar Development Relationship by Signing Two Commercial License Agreements
27 Feb 2019 Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers
26 Feb 2019 Immunotherapy Company TC BioPharm Partners with Trinity College Dublin to Develop V Delta 1 γδ T Cell-based Cancer Treatments
26 Feb 2019 ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million
25 Feb 2019 Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
25 Feb 2019 Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio
25 Feb 2019 Roche enters into definitive merger agreement to acquire Spark Therapeutics
24 Feb 2019 Boehringer Ingelheim and 3B Pharmaceuticals sign drug discovery collaboration
24 Feb 2019 Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
21 Feb 2019 Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen
21 Feb 2019 Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies
21 Feb 2019 Merck to Acquire Immune Design

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up